RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
2015 · Nature Communications · 619 citations
https://doi.org/10.1038/ncomms7377
T
Teresa Morán
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
323
Papers
18.7K
Citations
49
h-index
105
i10-index
Teresa Morán is an academic researcher from Universitat Autònoma de Barcelona. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Cancer Genomics and Diagnostics. The author has an h-index of 49, co-authored 275 publications.
Papers by this author
worksEpidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway
2006 · Clinical Cancer Research · 91 citations
https://doi.org/10.1158/1078-0432.ccr-06-0627
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma
2015 · Lung Cancer · 88 citations
https://doi.org/10.1016/j.lungcan.2015.01.013
SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
2020 · Clinical & Translational Oncology · 59 citations
https://doi.org/10.1007/s12094-020-02295-w
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group
2021 · BMC Cancer · 14 citations
https://doi.org/10.1186/s12885-021-07922-5
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial
2023 · British Journal of Cancer · 9 citations
https://doi.org/10.1038/s41416-023-02514-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat